Fennec Pharmaceuticals (TSE:FRX) Trading Up 7.6%
Fennec Pharmaceuticals Inc (TSE:FRX) was up 7.6% during mid-day trading on Thursday . The stock traded as high as C$6.77 and last traded at C$6.77, approximately 1,011 shares changed hands during trading. A decline of 28% from the average daily volume of 1,406 shares. The stock had previously closed at C$6.29.
The firm’s 50-day moving average price is C$6.31 and its 200-day moving average price is C$5.78. The stock has a market capitalization of $116.39 million and a PE ratio of -10.34.
Fennec Pharmaceuticals (TSE:FRX) last announced its earnings results on Friday, August 9th. The biopharmaceutical company reported C($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.19) by C($0.13).
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Further Reading: How Investors Use a Balance Sheet
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.